Lethargic Depression Study
Phase 3
Completed
- Conditions
- EpilepsyMajor Depressive Disorder (MDD)
- Registration Number
- NCT00064467
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.
- Detailed Description
A Multicenter, Double-Blind, Placebo-controlled comparison of the efficacy and safety of flexible dose extended-release bupropion (HCl) 300-450 mg/day and placebo administered for eight weeks for the treatment of adult outpatients with major depressive disorder including symptoms of decreased energy, pleasure, and interest
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 268
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from randomization on the Inventory of Depressive Symptomatology, self report and clinician rated.
- Secondary Outcome Measures
Name Time Method Percent of responders. Percent of remitters. Quality of Life Enjoyment and Satisfaction Questionnaire.
Trial Locations
- Locations (1)
GSK Investigational Site
🇺🇸San Antonio, Texas, United States